Evidence map›Paper›PMID 42536426›Full record

ArticleBJS open2026

Perioperative outcomes and long-term survival following resection of gallbladder cancer in older adults: retrospective study.

Anita Balakrishnan, Petros Barmpounakis, Nikolaos Demiris, Bodil Andersson, Alejandro Brañes, Xavier de Aretxabala, Paul Gibbs, Simon J F Harper, Emmanuel L Huguet, Asif Jah and 10 more

Abstract readMulticenter Study
In one paragraph

Article in BJS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anita BalakrishnanCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.ORCID 0000-0002-9172-3938
Petros BarmpounakisCambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Nikolaos DemirisCambridge Clinical Trials Unit-Cancer Theme, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Bodil AnderssonDepartment of Surgery, Lund University, Skane University Hospital, Lund, Sweden.
Alejandro BrañesDepartment of HPB Surgery, Hospital Dr Sotero del Rio, Santiago, Chile.ORCID 0000-0002-1512-1046
Xavier de AretxabalaDepartment of Digestive Surgery, Hepato-Pancreato-Biliary Surgery Unit, Surgery Service, Gallbladder Consortium Chile, Sotero del Rio Hospital and Clinica Alemana, Santiago, Chile.
Paul GibbsCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Simon J F HarperCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Emmanuel L HuguetCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Asif JahCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Vasilis KosmoliaptsisCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Javier LendoireDepartment of Surgery, University of Buenos Aires, Hospital Dr Cosme Argerich, Buenos Aires, Argentina.
Siong S LiauCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Shishir K MaithelDivision of Surgical Oncology, Robert H. Lurie Comprehensive Cancer Centre, Northwestern University, Chicago, Illinois, USA.
Jack L MartinCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Colin NoelGastrointestinal Surgery and HPB Surgery, Department of Surgery, University of the Free State, Bloemfontein, South Africa.
Raaj K PraseedomCambridge HPB Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Alejandro SerrabloDepartment of HPB Surgery, Miguel Servet University Hospital, Zaragoza, Spain.
Volkan AdsayDepartment of Pathology, Koç University Hospital, Istanbul, Turkey.
OMEGA Study Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGallbladder cancer (GBC) is a rare but aggressive disease, and surgical resection remains the only potential curative treatment. Although tumour-related effects on prognosis are well established, the impact of age is less understood. This study aimed to evaluate the influence of age on overall survival (OS), recurrence-free survival (RFS), and perioperative complications in GBC.

methodsData from patients undergoing curative resection for GBC at 133 centres across 41 countries between 2010 and 2020 were analysed to determine the prognostic association of age ≥ 75 years with OS, RFS, and morbidity. Propensity score matching was used to address confounders between the two age groups.

resultsIn all, 4138 patients underwent surgery for GBC. Patients with macroscopic tumour remaining after surgery, metastatic disease, only high-grade dysplasia were excluded leaving 3676 patients for analyses. Full data on all relevant parameters was available for 2072 patients aged < 75 years and 633 patients aged ≥ 75 years. Patients aged ≥ 75 years had more co-morbidities, underwent less extensive surgery or lymphadenectomy, and received adjuvant chemotherapy less frequently than younger (< 75 years) patients. Age ≥ 75 years was associated with poorer OS in both the unmatched (hazard ratio (HR) 1.34; 95% confidence interval (c.i.) 1.14 to 1.56; P < 0.001) and matched cohorts (HR 1.31; 95% c.i. 1.12 to 1.54; P < 0.001) cohorts, but was not associated with RFS or 1-year survival. Tumour extent and nodal stage had the greatest association with OS and RFS. Age was not associated with increased complications in either the unmatched (odds ratio (OR) 1.11; 95% c.i. 0.85 to 1.45; P = 0.400) or matched (OR 0.90; 95% c.i. 0.72 to 1.12; P = 0.353) cohorts.

conclusionsOlder adults received less extensive surgery and infrequent adjuvant chemotherapy. Age ≥ 75 years was associated with poorer OS following GBC resection but comparable complication rates to younger adults. Older adults of sufficient fitness should not be denied curative treatment based on age, and oncological benefit should be balanced against perioperative risk to personalize treatment and optimize surgical outcomes.

Indexed as

CholecystectomyGallbladder NeoplasmsPostoperative ComplicationsAgedAged, 80 and overAge FactorsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansLymph Node ExcisionMaleMiddle AgedPrognosisPropensity ScoreRetrospective Studiescholangiocarcinomagallbladder cancerolder adultssurgery

Identifiers

PMID42536426
PMCPMC13426238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.